Sumatriptan nur Darreichungsformen NAS, FERT, PEN, ILO (N02CC01)

TENDER DESCRIPTION

The Kaufmännische Krankenkasse - KKH (hereinafter referred to as KKH) pursues the objective of concluding discount agreements pursuant to Section 130a(8) of SGB V with all suitable pharmaceutical companies regarding the active ingredient specified under BT-21-Lot (ATC) and, if applicable, restricting them to certain dosage forms within the framework of the so-called "Open-House procedure". Subject to uniform contract terms and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion and/or accession to a discount agreement pursuant to Section 130a(8) SGB V for the aforementioned active ingredient. Interested pharmaceutical companies may request the participation documents as well as the contract at the contact address stated. A prerequisite for concluding a contract is that the interested pharmaceutical company submits the requested participation documents fully completed and signed. A contract will be concluded with each pharmaceutical company that meets the participation requirements. No exclusivity is provided. Accession and/or contract conclusion may take place at any time and under…

TENDER BRIEF

TENDER DOCUMENTS